Skip to content

The use of a Real Time Medication Monitoring system (RTMM) for the improvement of adherence to inhaled corticosteroids in children with asthma.

The use of a Real Time Medication Monitoring system (RTMM) for the improvement of adherence to inhaled corticosteroids in children with asthma. - e-Monitoring of Asthma Therapy to Improve Compliance in children (e-MATIC)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON36539
Enrollment
220
Registered
2011-10-03
Start date
2011-04-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

All children receive an RTMM-device, but only in the intervention group text-messages are sent to the parents and - in case the child has a mobile phone - to the child to warn that a dose is at risk

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
2 Years to 11 Years

Inclusion criteria

Inclusion criteria: * children 4-11 years old * diagnosed with asthma for at least 6 months * ICS use for at least 3 months using a pMDI * at least one parent or care giver has a mobile phone

Exclusion criteria

Exclusion criteria: * patient resisting participation in the study

Design outcomes

Primary

MeasureTime frame
Primary outcome measure is defined as the number of prescribed dosages taken by the child in the correct timeframe (from 3 hours before untill 3 hours after the planned moment of inhalation)

Secondary

MeasureTime frame
Secondary outcome measures are asthma control, healthcare use and disease-specific quality of life collected through questionnaires, interviews and medical health records. Online focus groups and patient questionnaires will be used to collect data on parental and children*s acceptance of the RTMM system. An economic evaluation will be performed adopting a societal perspective, including all relevant healthcare costs and productivity loss of the parents. Furthermore, we will develop a decision-analytic model that includes different levels or forms of adherence and the outcomes, both clinical and costs, attributed to each level or form of adherence as well as different price levels for RTMM.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)